Posts tagged ‘cancer treatments’

According to a new Northwestern Medicine study, a middle aged woman, say of 54, is likely to suffer from hip fracture if she is a breast cancer survivor. Though hip fracture is not common in a middle aged woman, it is a likely development in those who have gone through the therapies for breast cancer treatment.

Researchers are of the opinion that breast cancer treatment causes early menopause and along with breast cancer drugs it leads to weakening of bones, which later causes hip fractures. The study has been published in the February issue of Clinical Cancer Research.

Hip fractures are rare cases in people under the age of 70. Yet Beatrice Edwards, a physician of Northwestern Medicine observed that quite a few breast cancer survivors in their 50s were complaining of the problem.

Researchers did a meticulous study of 6 of such women over one year assessing the type of breast cancer they had, the treatment they were provided and the consequence of hip fracture on their life. Beatrice Edwards remarks that these women reported difficulty in climbing stairs and doing their daily chores even a year after the fracture.

Surprisingly, most of the women did not have osteoporosis but had lower bone mineral density suggesting that the bone structure may have been altered following chemotherapy and early menopause.

These women had been provided treatment for early-stage breast cancer including lumpectomy, chemotherapy and radiation therapy with cytoxan and adriamycin one to four years before fracture occurred. At the time of the fracture, all the women were perimenopausal.

Four of these six women received aromatase inhibitors (AIs) as a part of their treatment and studies have associated AIs with possible bone loss in women. Edwards cites that bone loss is a possible adverse effect of breast cancer drugs but further research needs to be done before the mode of treatment is changed.

Source: http://www.eurekalert.org/pub_releases/2011-02/nu-phf020111.php

A partnership between the U.S. company Jennerex Inc. known for developing cancer drugs and the French biotech firm called Transgene SA (TNG.FR) was announced on Wednesday (8th Sept 2010). Both the companies entered into a treaty which will allow them to sell cancer specific drugs across Russia, Europe and the Middle East. The drugs will accomplish to target and destroy the cancerous cells of the body.

The joint statement issued by them states that they will join forces to develop JX-594, which had been developed by Jennerex Inc. initially and had seemed promising as far as the treatment of cancers affecting the liver, colon, kidney, and lungs are concerned.  The malignant Melanoma had also responded well to the treatment.

The French company has an equity stake in Jennerex Inc. now. The new arrangement will enable the US based company to earn handsomely from royalty figures as well as milestone payments. The payments are expected to be upwards of $116 million whereas the royalties are likely to be in double digits. It will also get a share in the profits gained from the five major countries of Europe and will have a stake in the promotion as well. The USA rights are also expected to be retained by Jennerex Inc.

David Kirn, the chief executive for Jennerex Inc. said that the company hopes to achieve much by making use of Transgene’s knowledge and experience, especially when it comes to immunotherapies. JX-594 can also be marketed properly all across the major nations by exploiting the latter’s established relationships with all the regulatory bodies of Europe.

The future plans will focus on containing the colorectal cancer as well as the Hepatocellular Carcinoma. JX-594 will address both the  first- as well as the second- line of treatment of the liver cells.  The companies have also planned a series of studies which aim at colorectal cancer patients including those who are immune or intolerant to the drug Erbitux.

The drug JX-594  is expected to attack the cancerous cells in a threefold manner. It will seek to destroy the cells by viral replication, cut off the blood supply to the malignant tumors as well as help to stimulate the immune system of the body

Source: http://online.wsj.com/article/BT-CO-20100908-705853.html
www.transgene.com